Edesa Biotech Reports Q4 GAAP EPS of -$1.27, Beating Expectations by $0.51

Edesa Biotech reported FY GAAP EPS of -$1.27, beating expectations by $0.51. As of September 30, 2022, the company had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Edesa also received $3.4 million in net proceeds from common shares sold under an at-the-market offering program after the fiscal year end.